clinicalRSVP.com, the participant registry that prevents research volunteers from enrolling in overlapping and concurrent research studies, announced that all seven (7) sites making up the original clinicalRSVP user network, including Clinical Pharmacology of Miami (one site), Comprehensive Clinical Development (three sites), Elite Research Institute (one site), and Seaview Research Inc. (two sites), have agreed to extend their commitment to the clinicalRSVP network through 2012 and beyond.
In 2009, this group of sites was the first in North America to adopt a subject registry for the purpose of preventing dual enrollment, thereby increasing data integrity and participant safety for their clients. Since inception, the clinicalRSVP network has grown to include 18 Phase I Units across the United States and Canada, representing more than 20 percent of the North American Phase I beds.
With ever-growing support from sponsors and sites alike, the mission of clinicalRSVP.com is to provide a single North American registry for investigators to confidentially and securely verify subject eligibility requirements prior to enrollment, thereby improving data integrity for sponsors and trial safety for participants.
“Ensuring our participants’ safety and facilitating rapid study start-up are the primary focuses for us at Comprehensive Clinical Development,” said Dr. Rae DelVecchio, Senior Vice President, Early Phase Operations. “We want our sponsors and participants to have total confidence in every aspect of our business and clinicalRSVP is a key component of our enrollment process.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.